Sacituzumab Govitecan and Toripalimab for First-Line Advanced Triple-Negative Breast Cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and toripalimab (an immunotherapy)—as the first treatment for advanced triple-negative breast cancer. The goal is to see if this pair works better than standard treatments, and to look for biomarkers that might predict who benefits most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have advanced triple-negative breast cancer that has not been treated with chemotherapy, targeted therapy, or immunotherapy for advanced disease.
- You have at least one tumor that can be measured by scans (CT or MRI).
- You are willing to receive the study treatment: a combination of sacituzumab govitecan (a targeted chemotherapy antibody) and toripalimab (an immunotherapy drug).
- You do not have symptoms from brain metastases that need urgent treatment, and you have not had prior treatment targeting HER2, Trop-2, PD-1/PD-L1, or similar drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, Sacituzumab Govitecan and Bevacizumab, for people with advanced triple-negative breast cancer that has already been treated. The goal is to see if the combination works better than standard treatments.
This trial tests a new drug combination (Trop-2 antibody-drug conjugate plus other therapies) for advanced triple-negative breast cancer that has spread or come back. It may offer a new option for people who have had only 1–2 prior chemotherapies and have not used immunotherapy or anti-angiogenic drugs before.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) for people with advanced triple-negative breast cancer that has progressed after earlier treatments. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs, sacituzumab govitecan (Sac-TMT) and toripalimab, as a first treatment for women with advanced triple-negative breast cancer that tests positive for a protein called PD-L1. The goal is to see if this combination is safe and effective in shrinking or controlling the cancer.
This study compares two combinations of drugs for people with a specific type of advanced breast cancer called triple-negative, which is PD-L1 positive. One combination uses sacituzumab govitecan, a targeted drug, with toripalimab, an immunotherapy. The other uses toripalimab with nab-paclitaxel, a chemotherapy. The goal is to see which combination works better.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted therapy) and Q901 (a study drug that blocks a protein needed for cancer cell growth)—in people with advanced triple-negative breast cancer who have already tried other treatments. The goal is to see if this combination can shrink or control the cancer.
Hear when a new TNBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.